ESR1 and breast cancer: Studies of hormone-regulated cancers, such as breast cancer and prostate cancer, have shown that pathogenic dysregulations of gene expression are mediated through risk variants altering binding affinities of master TFs, such as FOXA1, ESR1, and AR.